March 17, 2022
17 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Veterans Affairs (VA) sites added to validation study with first Veteran enroled Key lung cancer specialist, Dr Drew Moghanaki, appointed to Scientific Advisory Board LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its pivotal clinical study to evaluate the […]
• Read MoreMarch 8, 2022
8 March 2022 LungLife AI, Inc. (the "Company" or "LungLife") Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its full year results for the year ended 31 December 2021 on Monday 28 March 2022. Investor presentation Paul Pagano, Chief Executive Officer, and David […]
• Read MoreFebruary 2, 2022
2 February 2022 LungLife AI, Inc. (the “Company” or “LungLife”) First patient enrolment for LungLB® validation study LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has enrolled its first patient in its pivotal clinical study to evaluate the LungLB® test in subjects presenting with indeterminate lung nodules. The […]
• Read MoreJanuary 4, 2022
4 January 2022 LungLife AI, Inc. (the “Company” or “LungLife”) CPT® Code granted by American Medical Association Successful grant marks first step facilitating commercial reimbursement LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer announces it has been granted a CPT® Proprietary Laboratory Analyses (PLA) code for its LungLB® […]
• Read MoreNovember 22, 2021
19 November 2021 LungLife AI, Inc. (the “Company” or “LungLife”) LungLife AI Clinical Laboratory achieves CAP accreditation Independent inspection confirms highest standard of care for laboratory patients LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its clinical laboratory in Thousand Oaks, California […]
• Read MoreNovember 22, 2021
10 November 2021 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Application LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the “Block Admission”) has been made to the London Stock Exchange for up to 1,356,139 common shares of US […]
• Read MoreOctober 12, 2021
12 October 2021 LungLife AI, Inc. (the “Company” or “LungLife”) PLA Code application submitted in first step in reimbursement process LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical […]
• Read MoreSeptember 9, 2021
9 September 2021 LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer enhanced by artificial intelligence, announces its maiden unaudited half-year report for the six months ended 30 June 2021 following admission to trading on AIM on 8 […]
• Read MoreSeptember 3, 2021
3 September 2021 LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that its maiden unaudited half-year report for the six months ended 30 June 2021 will be announced on Thursday 9 September 2021. […]
• Read More
LungLife AI licensure/accreditation information posted here.